Select login type
xCHOOSE A PAGE TO ACCESS
x- WGXI Patient Involvement: Workplans, drafts, TC notes ...
- WGXI Patient Involvement: Background Documents
- WGXI Patient Involvement: Face-to-face meetings
- WGXII Benefit-risk Working Group Documents
- WGXVI Development Safety Update Report Working Group Documents
- WGXII Benefit-risk Working Group Documents
- WGXIII Real-world Data Working Group Documents
- SCAR Working Group Documents
- Educational Standards Working Group Documents
- Good Governance Practice for Research Institutions Working Group Documents
- Pharmacoepidemiology for Public Health Working Group Documents
- MedDRA Labelling Groupings Working Group Documents
- Clinical Research in Resource-limited Settings Working Group Documents
- Login
The role of adverse event follow-up in advancing the knowledge of medicines and vaccines safety: a scoping review
- Home
- The role of adverse event follow-up in advancing the knowledge of medicines and vaccines safety: a scoping review
The primary objective of this scoping review is to understand and evaluate the concept, implementation, frequency, and value of “follow-up” in the context of adverse event (AE) assessment. Secondary objectives include providing an overview of various definitions of “follow-up,” describing the requirements and studies evaluating follow-up methods, and assessing how often follow-up is undertaken in assessing an AE, by whom, and its value.